BSE filing, NSE: VIVANZA. Summary written from the filing by ALFA Finder's alert engine.
Vivanza Biosciences Ltd: key numbers
- Share price
- ₹1.50
- Market cap
- ₹6.00 Cr
- Revenue (annual)
- ₹115.9 Cr
- Net profit (annual)
- ₹0.39 Cr
- P/E (TTM)
- 13.2×Sector 46.1×
- Promoter holding
- 20.02%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vivanza Biosciences Ltd
All →Vivanza Biosciences Board Meeting Date
Vivanza Biosciences has scheduled a Board meeting on November 3, 2026 to approve unaudited Q2 and H1 FY27 financial results. No other material agenda items are listed.
Vivanza Biosciences Other Announcement
Vivanza Biosciences Ltd has filed a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations for the quarter ended September 30, 2026.
Vivanza Biosciences Annual General Meeting
Vivanza Biosciences has convened its 44th AGM on September 11, 2026 via VC/OAVM. Nine agenda items cover financial statements, director appointments, and borrowing limit approvals.
Vivanza Biosciences Annual Report
Vivanza Biosciences Limited has scheduled its 44th Annual General Meeting for September 11, 2026. The company also released its full Annual Report for the financial year 2025-26.
Vivanza Biosciences Board Meeting Date
Vivanza Biosciences has scheduled a board meeting for August 17, 2026, to discuss the AGM, financial reports, and various corporate authorizations under the Companies Act.
Vivanza Biosciences Q1 FY27 Results: Net Profit ₹0.1 Cr, Up 0.0% YoY
Vivanza Biosciences Ltd reported revenue from operations of ₹9.3 Cr (+4.5% YoY) and net profit of ₹0.1 Cr (+0.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.1 Cr · +0.0% YoY
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.